martedì, 16 aprile 2024
Medinews
13 Aprile 2018

FDA Grants Duvelisib Priority Review for CLL and Follicular Lymphoma

April 9, 2018 – The FDA has granted a priority review to a new drug application (NDA) for duvelisib for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma. The NDA includes supporting data from the phase III DUO trial and the phase II DYNAMO study. In DUO, duvelisib … (leggi tutto)

TORNA INDIETRO